# Retraction: Salidroside enhances the anti-cancerous effect of imatinib on human acute monocytic leukemia via the induction of autophagy-related apoptosis through AMPK activation

**Authors:** Chiyu Ge, Junli Zhang, Feng Feng

PMC · DOI: 10.1039/d4ra90050b · 2024-04-29

## TL;DR

This retraction notice informs that a 2019 study on how salidroside boosts imatinib's effect against leukemia is being retracted.

## Contribution

The paper formally retracts a prior study, indicating issues with its validity or integrity.

## Key findings

- The original study's claims about salidroside and imatinib's combined effect are no longer considered valid.
- The retraction highlights the importance of verifying scientific results before publication.

## Abstract

Retraction of ‘Salidroside enhances the anti-cancerous effect of imatinib on human acute monocytic leukemia via the induction of autophagy-related apoptosis through AMPK activation’ by Chiyu Ge et al., RSC Adv., 2019, 9, 25022–25033, https://doi.org/10.1039/C9RA01683J.

## Linked entities

- **Proteins:** PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1)
- **Chemicals:** salidroside (PubChem CID 159278), imatinib (PubChem CID 5291)

## Full-text entities

- **Genes:** PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 5563] {aka AMPK, AMPK2, AMPKa2, PRKAA}
- **Diseases:** acute monocytic leukemia (MESH:D007948)
- **Chemicals:** Salidroside (MESH:C009172), imatinib (MESH:D000068877)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC11056948